VERAXA Biotech AG, a portfolio company of Xlife Sciences AG, has made significant strides towards its NASDAQ listing with the filing of a prospectus (F-4 Filing) with the U.S. Securities and Exchange Commission. This registration statement includes essential details about the planned business combination with NASDAQ-listed SPAC Voyager Acquisition Corp. The transaction is valued at approximately $1.3 billion, with VERAXA shareholders set to receive around 130 million shares of the merged entity. The anticipated pro-forma market capitalization post-merger is approximately $1.64 billion, assuming a share price of $10.00. VERAXA is also conducting a "crossover" financing round expected to conclude before the merger's completion, targeted for the fourth quarter of 2025. This development underscores VERAXA's progress in oncology therapies and aligns with Xlife Sciences' strategy of merging academic innovation with market-driven commercialization.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.